A new video by our ODELIA (Open Consortium for Decentralized Medical Artificial Intelligence) project has just been released. offering a captivating glimpse into the world of Swarm Learning and its impact on healthcare. Learn more about how ODELIA aims to revolutionise medical AI, ensuring privacy, collaboration, and better patient outcomes:

Exciting News! The ESR Research Seed Grants 2024 are here! 🎉

The European Society of Radiology (ESR) and the European Institute for Biomedical Imaging Research (EIBIR) are thrilled to introduce the ESR Research Seed Grant Programme’s third call for proposals!

🌍 2024 Thematic Areas:
1) Contrast-enhanced Imaging
2) Imaging Surveillance in Cancer Treatment

💰 Funding Amount: €5,000 – €7,000
🗓️ Deadline: December 10, 2023

📢 Up to 10 seed grants to be awarded in 2024!

💻 To learn more about eligibility criteria and guidelines, please visit the following link: ESR Research Seed Grant

This is your chance to turn your vision into a reality and make a meaningful impact in the field of radiology. 📊 We are looking forward to your applications! 🔬

EUCAIM is looking for your feedback! The EU-funded EUCAIM project coordinated by EIBIR is reaching out to potential end-users and stakeholders through a recently published Stakeholder Survey. This survey is carried out in order to understand your expectations and to identify essential aspects for future engagement and collaboration with EUCAIM’s platform!

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.

Click here to access the survey

Responses are anonymous, unless you leave your contact details for more information about workshops and training events. In case of questions, please contact pgordebeke@eibir.org.

The EUCAIM project is establishing the Cancer Image Europe platform, a robust and trustworthy space for researchers, clinicians, and innovators to access diverse cancer images. This platform will facilitate benchmarking, testing, and piloting of AI-driven technologies. EUCAIM is one of the flagship activities under the EU’s European Cancer Imaging Initiative.

To learn more about EUCAIM and the Cancer Image Europe platform, the project has prepared a short video:

To follow EUCAIM’s journey, please visit their website and connect with them on social media:

EUCAIM’s Website

EUCAIM’s LinkedIn

September 29, 2023

Vienna, Austria – The EUCAIM consortium and the European Commission are excited to announce the first public release of its platform, Cancer Image Europe, marking a major milestone in the project’s development and an exciting step towards achieving its vision and goals. The first platform release brings benefits to researchers, clinicians and AI innovators across Europe and paves the way for the future of cancer diagnosis and treatment.

Key features and highlights of EUCAIM’s first platform release include:

• A public catalogue of cancer imaging datasets from the repositories of the EU-funded AI for Health Imaging projects, following a common metadata schema.
• A federated searching tool to understand the information available in the federated providers.
• Full integration with the Life Science Login Authentication and Authorisation Infrastructure.
• Reusing and adding value to key components of EU-funded research projects and infrastructure in the field of cancer.

Commenting on this milestone achievement, Ignacio Blanquer, leading the EUCAIM infrastructure development, says “this early prototype of EUCAIM is a proof of concept for the federation model pursued in EUCAIM. It will be the basis for a fully fledged infrastructure for sharing, reusing and exploiting cancer imaging data, especially using AI techniques.”

Prof. Luis Martí-Bonmatí, Scientific Coordinator of EUCAIM, adds that “this is the first step towards the set-up of the largest known-to-date cancer imaging infrastructure in Europe. Over the next months, the EUCAIM project will continue to extend the functionalities of the platform, linking to other research repositories, screening programmes and data warehouses towards its next upgrade, expected to be released in June 2024”.

By releasing the first version of Cancer Image Europe, sharing of cancer images and supporting clinical data is facilitated and collaboration between researchers, clinicians and AI innovators across Europe is stimulated. The platform aims to accelerate the pace of AI development and other data-intensive cancer research activities, thereby enabling and empowering scientific breakthroughs that will shape the future of cancer diagnosis and treatment. The project’s goals and vision contribute to the strategic objectives of the European Union’s initiatives and foster innovation and research.

With the Cancer Image Europe infrastructure, the EUCAIM project addresses the fragmentation of existing cancer image repositories. A distributed Atlas of Cancer Imaging with over 60 million anonymised cancer image data from over 100,000 patients will be established as part of future updates, and the infrastructure will be fully in alignment with the European Health Data Space. The data will be accessible to clinicians, researchers and innovators across the EU for the development and benchmarking of trustworthy AI tools.

The EUCAIM project is a cornerstone of the European Commission-initiated European Cancer Imaging Initiative, a flagship of the Europe’s Beating Cancer Plan, which aims to foster innovation and deployment of digital technologies in cancer treatment and care, to achieve more precise and faster clinical decision-making, diagnostics, treatments and predictive medicine for cancer patients.

For more information about the first release of the Cancer Image Europe platform and the EUCAIM project, please visit cancerimage.eu.

Greats news! On September 7th, the EU and the UK  have reached a political agreement on the UK’s participation in Horizon Europe.

As of 1 January 2024, U.K. researchers will be able to participate in Horizon Europe on a par with their EU counterparts and will have access to the scheme’s funding.

For more detail on this decision, read the press statement issued by the EC.

We are delighted to announce the appointment of Professor Regina Beets-Tan as the new Scientific Director of EIBIR. Professor Beets-Tan brings with her a wealth of knowledge and expertise that will undoubtedly contribute to further enhancing our organisation in supporting European biomedical imaging research and networking activities between institutes and disciplines.

Professor Beets-Tan’s profile and achievements speak volumes about her outstanding credentials and dedication to advancing the field of biomedical imaging research. She chairs the department of Radiology at the Netherlands Cancer Institute and is Professor of Radiology at the University of Maastricht, The Netherlands and adjunct Professor of Abdominal and Oncological Radiology at the University of Southern Denmark.  Professor Beets-Tan is the former Chair of the Board of Directors of the European Society of Radiology (ESR), member of the EU mission board for cancer and of the board of the European Cancer Organisation. Her expertise in multidisciplinary research and collaborations will undoubtedly drive our work together.

We are thrilled to welcome her on board and eagerly anticipate the exciting new frontiers we will explore together under her visionary leadership.

Professor Beets-Tan pointed out that “multidisciplinary research in biomedical imaging is not merely a pursuit of knowledge but a catalyst for change. It’s through collaboration and bridging the gaps between disciplines that we can unlock the potential of biomedical research to move forward the field of precision medicine.”  She further stated that “it’s with great honor that I assume the responsibility of leading this esteemed organisation. I am grateful for the opportunity to build further upon the outstanding work of my predecessor Professor Gabriel Krestin and guide EIBIR towards new horizons”.

We would also like to take this opportunity to extend our heartfelt gratitude and appreciation to our outgoing Scientific Director, Professor Gabriel Krestin. Over the past nine years, Professor Krestin has been instrumental in driving the growth and success of EIBIR. Under Professor Krestin’s guidance, our organisation has made remarkable advancements, positioning us as a leading entity in supporting scientists and securing funding for their projects.

Professor Krestin commented on his time at EIBIR: “I find it hard to say goodbye to EIBIR after 9 years as its Scientific Director and 8 years as Chair of the General Meeting of Shareholders before that. EIBIR was my “baby” and I leave it now in a stage of an almost “grown-up”. This growth would not have been possible without the engagement of the extremely talented EIBIR Team in our Vienna office under the guidance of Mrs. Monika Hierath. They are the body and the soul of EIBIR and I am happy that they will continue to support multidisciplinary collaborative research in biomedical imaging in Europe in the years to come.”

To Professor Kerstin, we extend our warmest congratulations on an incredibly successful 9-year term as Scientific Director. Your achievements and unwavering commitment have left an indelible mark on our organisation. The knowledge and inspiration you have imparted will continue to shape the future of our organisation’s endeavours.

The SIMPLERAD project, conducted by a consortium of EIBIR, EANM Forschungs GmbH, and EFOMP, is a SAMIRA study on the implementation of the Euratom and the EU legal bases with respect to the therapeutic uses of radiopharmaceuticals. Since May 2022, the consortium has synthesised collected information and formulated a guidance document aiming for coherent implementation of the European legal requirements with respect to therapeutic nuclear medicine. Relevant interested professionals from European and national authorities, competent authorities, nuclear medicine, clinical communities, patient organisations, radiopharmaceutical industry, etc., are invited to attend and discuss the consortium’s achievements and draft guidelines.

More information, including an up-to-date programme, can be found on the project website. Formal invitations will soon be sent to target groups, but inquiries can be made to Nathan D. Peld of the EIBIR office.

📢 Attention! Abstract submission deadline for the European Radiation Protection Week 2023 has been extended to Sunday, June 11th at 23:59 CET.

Submit your abstract & register today:
🔗 https://ucd.ie/ERPW2023/

The European Radiation Protection Week (ERPW) is an annual, multidisciplinary event which brings together experts and addresses current and emerging topics related to radiation protection.